Pharmaceutical

Bayer applies for EU approval of menopause drug elinzanetant

Bayer notches up pressure on rival Astellas’ Veozah with an EU marketing authorisation application for its hot flash relief pill.

Oct 16, 2024 - 04:00
Bayer applies for EU approval of menopause drug elinzanetant
Bayer notches up pressure on rival Astellas’ Veozah with an EU marketing authorisation application for its hot flash relief pill.
Read the original article

Tags:

Previous Article

Lilly touts Omvoh’s superiority over J&J’s Stelara in Crohn’s

Next Article

Transgene’s stock drops after Phase II cancer jab trial misses primary endpoint

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

ESC 2024: Amvuttra data signals positive prospects in cardiomyopathy for Alnylam

ESC 2024: Amvuttra data signals positive prospects in c...

Aug 31, 2024

Moderna’s plan to make a single vaccine for Covid, influenza, and RSV is on track

Moderna’s plan to make a single vaccine for Covid, infl...

Oct 6, 2023

DF-4101 by AbbVie for Non-Small Cell Lung Cancer: Likel...

Apr 21, 2024